- Home
- WWR vs BDSX Comparison
WWR vs BDSX Comparison
Compare WWR & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- BDSX
- Stock Information
- Founded
- WWR 1977
- BDSX 2005
- Country
- WWR United States
- BDSX United States
- Employees
- WWR N/A
- BDSX N/A
- Industry
- WWR Metal Mining
- BDSX Precision Instruments
- Sector
- WWR Basic Materials
- BDSX Health Care
- Exchange
- WWR Nasdaq
- BDSX Nasdaq
- Market Cap
- WWR 48.0M
- BDSX 53.2M
- IPO Year
- WWR N/A
- BDSX 2020
- Fundamental
- Price
- WWR $0.79
- BDSX $0.40
- Analyst Decision
- WWR Strong Buy
- BDSX Strong Buy
- Analyst Count
- WWR 2
- BDSX 5
- Target Price
- WWR $2.00
- BDSX $1.75
- AVG Volume (30 Days)
- WWR 2.1M
- BDSX 1.5M
- Earning Date
- WWR 08-07-2025
- BDSX 08-07-2025
- Dividend Yield
- WWR N/A
- BDSX N/A
- EPS Growth
- WWR N/A
- BDSX N/A
- EPS
- WWR N/A
- BDSX N/A
- Revenue
- WWR N/A
- BDSX $76,556,000.00
- Revenue This Year
- WWR N/A
- BDSX $17.29
- Revenue Next Year
- WWR N/A
- BDSX $29.33
- P/E Ratio
- WWR N/A
- BDSX N/A
- Revenue Growth
- WWR N/A
- BDSX 25.70
- 52 Week Low
- WWR $0.45
- BDSX $0.17
- 52 Week High
- WWR $1.32
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- WWR 57.08
- BDSX 53.61
- Support Level
- WWR $0.65
- BDSX $0.37
- Resistance Level
- WWR $0.79
- BDSX $0.43
- Average True Range (ATR)
- WWR 0.06
- BDSX 0.05
- MACD
- WWR -0.01
- BDSX -0.00
- Stochastic Oscillator
- WWR 72.53
- BDSX 45.66
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.